New trial combines drugs with surgery or radiation to fight advanced prostate cancer
NCT ID NCT05649943
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Italian study is testing whether adding local treatment (radiotherapy or surgery) to standard apalutamide and hormone therapy can delay cancer progression in men with metastatic hormone-sensitive prostate cancer. About 566 participants will first receive drug therapy for 6 months, then be randomly assigned to continue drugs alone or add local treatment. The main goal is to see if the combination improves progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Apalutamide (Erleada) plus androgen deprivation therapy (hormone therapy), with or without local treatment (radiotherapy or radical prostatectomy)
What this could lead to
If successful, this could show that adding local treatment to standard drug therapy helps control metastatic prostate cancer longer, potentially improving survival without worsening side effects.
What could go wrong
This is a Phase 2/3 trial with 566 participants, but it is not yet complete. Adding local treatment may increase side effects without clear benefit, and results may not apply to all patients with metastatic prostate cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASST Santi Paolo e Carlo
NOT_YET_RECRUITINGMilan, Lombardy, 20153, Italy
Contact Email: •••••@•••••
Contact
-
European Institute of Oncology
NOT_YET_RECRUITINGMilan, Lombardy, 20141, Italy
Contact Email: •••••@•••••
Contact
-
Istituto Tumori Milano
RECRUITINGMilan, Mi, 20156, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact